Cargando…
Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses
BACKGROUND: Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood. METHODS: For a comprehensive analysis...
Autores principales: | Xia, Tao, Li, Keyu, Niu, Nan, Shao, Yingkuan, Ding, Ding, Thomas, Dwayne L., Jing, Hao, Fujiwara, Kenji, Hu, Haijie, Osipov, Arsen, Yuan, Chunhui, Wolfgang, Christopher L., Thompson, Elizabeth D., Anders, Robert A., He, Jin, Mou, Yiping, Murphy, Adrian G., Zheng, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962046/ https://www.ncbi.nlm.nih.gov/pubmed/35346322 http://dx.doi.org/10.1186/s13045-022-01253-z |
Ejemplares similares
-
Immune Gene Signatures and Immunotypes in Immune Microenvironment Are Associated With Glioma Prognose
por: Wang, Xiang-Xu, et al.
Publicado: (2022) -
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review)
por: Yang, Siqi, et al.
Publicado: (2023) -
Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
por: Osipov, Arsen, et al.
Publicado: (2019) -
Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses
por: Liu, Yu-Qing, et al.
Publicado: (2019) -
Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
por: Lee, Patrick C., et al.
Publicado: (2021)